Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Technology Type, Application & Components The global immunoassay market will witness a robust CAGR of 7.3%, valued at $24.30 billion in 2021, expected to appreciate and reach $45.82 billion by 2030, confirms Strategic Market Research. North America is poised to lead the industry, followed by Europe. Pathogens, such as bacteria, fungus, protozoa, worms, viruses, and prions, cause infectious diseases. The main function of the immunoassay is to defend the body from pathogens. Rapid pathogen identification from patient samples is critical for properly diagnosing and treating infectious disorders. The Three Categories of Pathogen Diagnostic Instruments Are: Microbiology Testing studies pathogens' characteristics, modes of transmission, and mechanisms of infection and growth (Diagnosis takes up to 7 days). Molecular Testing detects a molecule, often in low concentrations, as a marker of disease or risk in a sample taken from a patient. These tests are sensitive to viral nucleic acids. Hence the use of polymerase chain reaction (PCR) and other comparable nucleic acid amplification methods. (Diagnosed within a day) Immunoassays- They are similar to Molecular Testing but detect proteins and antigens. An assay is a process or a way of analyzing a substance to determine its quality or composition. Immunoassays are biochemical tests that use the binding ability of antibodies (immunoglobulin) and antigens (foreign substances) to detect and measure the concentration of target molecules. Traditional methods use cell culture to diagnose viruses, whereas most cultures take up to 7 days for accurate identification. Researchers and health care practitioners use immunoassay testing to detect various antibodies. Immunoassays are fast and accurate tests that can be performed on-site and in the lab to detect specific chemicals. When a patient is infected with a disease, the presence of antigens can be used to directly detect the infection. According to Global Burden of Disease (2017), Lower respiratory infections are the 3rd leading cause of early death and will remain the same till 2040. Procedure- Immunoassay testing uses antibodies to detect and identify small biological substances in the bloodstream and other bodily fluids. The procedure follows the concept that particular antigens bind to certain specific recently introduced antibodies, resulting in the stimulation of an immune response. Antibodies, such as nucleoproteins, hormones, and peptides, are highly specific to analytes (the substance in a test sample). Detection of analytes becomes highly successful through the formation of antigen-antibody complexes. A color change occurs, that indicates the presence of the analyte in question. The observed color symbolizes the number of targeted molecules present in the test solution. In most cases, immunoassays provide results back in 24 hours. EIAs are less time-consuming than cytotoxicity tests, are less expensive, and provide results in 1 to 6 hours. Cost- Test kits cost from $1.20 per test for ELISA to more than $30 for western blot. According to HTStec Limited's publication Automated Immunoassays Trends, the median capital cost of immunoassay automation already implemented was in the range of $40-$60,000. Benefits- Immunoassays can provide a fast, simple and more cost-effective detection than the conventional methods. It has high sensitivity and specificity, convenience, and the ability to achieve high throughput. Applications- Immunoassays have a wide application that includes: Diagnosis of diseases. Therapeutic drug monitoring. Clinical pharmacokinetics. Bioequivalence studies in drug discovery. Biopharmaceutical analysis. Sports anti-doping analysis. Pregnancy Test to detect the pregnancy marker. Environmental monitoring. Food testing. Types of Immunoassay Platforms Radioimmunoassay (RIA)- RIA is an immunoassay that uses radioactive isotopes (e.g., I-235) to label the antibody/antigen. It detects radioactivity to measure the antibody-antigen compound with very high sensitivity. Enzyme Immunoassays (EIA)- EIA is possibly one of the most popular immunoassays. Instead of radioactive isotopes, Enzymes (such as HRP and AP) are used as probes in EIA. These enzymes are frequently detected because their enzymatic reactions result in a visible color change. Fluoroimmnoassay (FIA)- FIA is analogous to RIA except that the label which is a fluorophore (e.g., FITC, phycoerythrin) rather than radioisotope. A detecting device can directly measure the fluorescence signal. Chemiluminescence immunoassay (CLIA)- CLIA is a method for determining sample concentrations based on the amount of luminescence produced by a chemical reaction. Colloidal Gold Immunochromatographic Assay- ICA, also known as lateral flow immunoassay, is a rapid test immunoassay to detect a target analyte's presence (or absence) in a sample (matrix) without the need for specialized and costly equipment. Electrochemiluminescence immunoassay (ECL)- When Electrochemiluminescent tags are triggered by electricity in the right chemical environment, they produce light. Types of Immunoassay Techniques Western Blotting-Western Blotting detects and identifies viral antigens (proteins usually on the surface of viruses) using antibodies against those particular proteins. Enzyme-Linked Immunosorbent Assays-ELISA (Enzyme-Linked ImmunoSorbent Assay) uses virus antigen to detect antibodies. Immuno-PCR -Compared to similar ELISA, I-PCR combines the simplicity and versatility of an enzyme-linked immunosorbent test (ELISA) with the exponential amplification capacity and sensitivity of PCR. Rapid Tests-The rapid test involves the same technique as ELISA. However, it is low in sensitivity and specificity as compared to ELISA. Enzyme-Linked Immunospot-It is a hybrid essay that combines the features of an MLR (Mixed leukocyte reaction), and ELISA used to determine HIV-1 specific CD8 T-cell responses. CD/DVD-based immunoassay- It includes the disk (grey), gold nanoparticle (red), a probe (green), analyte (yellow), and silver particle (blue). Key Industry Drivers - Rising Infections, Cancer Patients, Old Age Population, and Automation Rising Infections- Some of the conditions that may increase susceptibility to infectious diseases are cancers, particularly patients on chemo- or radiotherapy, leukemia, lymphoma, Hodgkin's disease, immune suppression (HIV infection), long-term steroid use, liver disease, hemochromatosis, diabetes, alcoholism, chronic kidney disease, and dialysis patients who are diagnosed by immunoassays. According to the WHO, the last decade witnessed 20% of death worldwide due to infections. The most common causes of death related to infectious diseases were lower respiratory infections (6.1%), diarrheal diseases (4.3%), HIV/AIDS (3.1%), tuberculosis (2.4%), malaria (2%), and measles (1.6%). Rising cases of Cancer Patients-The incidence of cancer is increasing steadily, which is expected to drive the demand for effective diagnostic methods such as immunoassay. This growth is due to chronic and infectious disorders like the COVID-19 outbreak. Infectious disorders including SARS-CoV2 (COVID-19), Hepatitis B, C, HIV, Dengue Malaria, Tuberculosis, and others are rising. According to the International Agency for Research on Cancer's GLOBOCAN 2020, there were 19.3 million new cancer cases and over 10.0 million cancer deaths in 2020. Rise in the old age population- Old people are more prone to chronic infectious and Immunodeficiency Diseases, which is driving the market's growth. According to World Population Ageing 2019, the number of people aged 65 years or over will double in 30 years. Meanwhile, the number of people aged 80 years or over will rise threefold. Automation-Fully automated immunoassays can provide high throughput, reproducibility, and ease of assay transfer. Process automation provides the dual benefits of time savings and reduction in operator-dependent variability. Restraints - Wide Adoption of Molecular diagnostics and Operational Hurdles Wide Adoption of molecular diagnostic tests-Despite the fact that many laboratories now utilize molecular assays to detect viruses, immunoassays are still commonly used in the identification process because of their speed, sensitivity, accuracy, cost-effectiveness, and convenience of use. Operational hurdles- Immunoassay reagents and kits face operating issues like cross-reactivity of antibodies, low detection limits of the available antibody, and false negatives. Opportunities Coverage - Various Opportunities Covered based on Evolution of Companion diagnostics, High Success rate, Increase in Incidence of Sepsis, Emergence of Condition-specific biomarkers. Evolution of Companion diagnostics - The drug diagnostic co-development model is commonly used to create companion diagnostic assays parallel with a medication. There is an increase observed in the number of predictive biomarker assays being developed in recent years to guide the usage of targeted cancer therapies. High Success rate - Immunoassays have grown in popularity in evaluating biological analytes due to their sensitivity, specificity, and ease of use. Furthermore, some immunoassay procedures are quick, precise, and simple to automate, needing minimal human intervention. The recent estimates published in The Lancet on the Performance characteristics of five immunoassays for SARS-CoV-2 accounted for sensitivity and specificity of more than 98%. Increase in Incidence of Sepsis - Sepsis is a fatal disease when the body's response to an infection causes tissue damage. While bacterial infections are the most prevalent cause of sepsis, they can also be caused by viral infections. As Per the global Immunoassay market report on the Epidemiology and Burden of Sepsis 2017, sepsis led to 20% of annual global deaths (11 million deaths) and affected 49 million people. The emergence of Condition-specific biomarkers - Many biomolecules, including antigens, DNA, mRNA, and enzymes, are used as biomarkers. However, protein biomarkers are the most common biomarkers used in medical diagnostics. Tumour tissues, serum, and other bodily fluids all contain biomarkers. The field of biomarker detection technology has made tremendous progress. Various biomarker detection approaches have been developed based on extremely specific identification biomarkers. According to the article published in Infection & Chemotherapy Journal, biomarkers can be used for risk stratification, diagnosis, monitoring of treatment responses, and outcome prediction. C-reactive protein, procalcitonin, different cytokines, and cell surface markers are among the 170 biomarkers that have been useful for diagnosing infections. Market Analysis Of Different Segments Covered in the Report Based on Type/ Platform Radioimmunoassay (RIA) Enzyme Immunoassays (EIA) Fluoroimmnoassay (FIA) Chemiluminescenceimmunoassay (CLIA) Electrochemiluminescence immunoassay (ECL) Colloidal Gold Immunochromatographic Assay Based on Technique Western Blotting Enzyme-Linked Immunosorbent Assays Immuno-PCR (I-PCR) Rapid Tests Enzyme-Linked Immunospot CD/DVD-based immunoassay Other Techniques Based on Application Infectious Diseases Respiratory Disease Oncology or Cancer Diagnostics Hematology Cardiology Endocrinology Thyroid Allergies Others Based on End-User Hospitals Pharma & Biotech Companies Clinical Laboratories Others Based on Product Reagents and Kits Analyzers Based on Specimen Type Blood Saliva Urine Others Based on Region North America Europe Asia-Pacific Latin America The Middle East and Africa Segments Analysis & Insights By Type/ Platform, Enzyme Immunoassays (EIA) is the most cost-effective since they are quick, easy to use, and do not require additional handling or disposal procedures. As a result, they control the majority of the market. By Technique, Enzyme-linked immunosorbent assay (ELISA) leads the market segment of Immunoscreening. Certain diseases aren't easy to identify with other means like swab tests. An ELISA blood test can help spot signs of infection or disease in your system. The gold standard of immunoassays is the enzyme-linked immunosorbent assay (ELISA), a labeled immunoassay. This very sensitive immunological test detects and measures molecules such as antibodies, antigens, proteins, glycoproteins, and hormones. The significant industry share is due to the high use of immunoassay tests to detect and diagnose cancer, chronic complications, and other infectious diseases. Based on application, the Infectious diseases segment is leading the global Immunoassay market share due to the high incidence of infectious diseases, rising number of regulatory approvals & product launches, increased Adoption of kits, and increasing demand for COVID-19 test kits. By End Users, the Hospital segment leads the market share by facilitating in-house diagnostic laboratories. The rise in infectious diseases, which are mostly Hospital Acquired Infections, are treatable in hospitals. The expanding number of tests performed in diagnostic labs, rising laboratory automation, availability of well-equipped immunoassay systems, rising prevalence of infectious disorders, and rising government initiatives drive this segment's expansion. The CDC estimates that Out of All 1.7 Million Hospital Acquired Infections (HAIs) in the US, 32% are urinary tract infections, 22% are surgical site infections, 15% are lung infections, and 14% are bloodstream infections. By Product Type, the Reagents and kits segment is destined to dominate the immunoassay reagents and devices market because of its increased use in illness detection and drug development. The large industry share is attributed to their repetitive purchase and high consumption for diagnostic purposes. By Specimen Type, the Blood segment is poised to lead the market share by revenue due to many tests requiring high specificity performed using blood samples. Blood tests provide a crucial picture of overall health and well-being. By Region, North America is expected to dominate the market. The surge in the market share is due to the rise in the prevalence rates of chronic disorders and infectious diseases. Furthermore, the growing elderly population and well-established healthcare infrastructure will boost the growth of the region's immunoassay reagents and devices market. In nations like the United States with established market economies, infectious diseases account for 4.2% of all disability-adjusted life years lost (DALYs), whereas chronic and neoplastic diseases account for 81%, according to estimates from the Global Burden of Disease Study. Asia-Pacific is projected to observe signs of growth during the forecast period due to the highest number of immunoassay reagents and device providers. According to the World Health Organization, ICU-acquired infections, such as UTIs and surgical-site wound infections, are two to three times greater in developing nations than in developed countries. Immunoassay Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 24.30 Billion The revenue forecast in 2030 USD 45.82 Billion Growth rate CAGR of 7.30% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Type/ Platform, By Technique, By Application, By End-user, By Product, By Specimen Type and By Region. By Type/ Platform Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoroimmnoassay (FIA), Chemiluminescence immunoassay (CLIA), Electrochemiluminescence immunoassay (ECL), Colloidal Gold Immunochromatographic Assay By Technique Western Blotting, Enzyme-Linked Immunosorbent Assays, Immuno-PCR (I-PCR), Rapid Tests, Enzyme-Linked Immunospot, CD/DVD-based immunoassay, Other Techniques By Application Infectious Diseases, Respiratory Disease, Oncology or Cancer Diagnostics, Hematology, Cardiology, Endocrinology, Thyroid, Allergies and Others By End-user Hospitals, Pharma & Biotech Companies, Clinical Laboratories, and Others By Product Reagents and Kits, and Analyzers By Specimen Type Blood, Saliva, Urine, Others By Region North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. Country Scope Canada, Germany, UK, US, Mexico, France, India, Japan, China, etc. Company Profiles BD, Bio-Techne, Abbott, Agilent Technologies, Beckman Coulter, BioCheck,bioMérieux SA, Merck KGaA, Ortho Clinical Diagnostics, Randox Laboratories Ltd, Siemens, Thermo Fisher Scientific, Shenzhen Mindray Bio-Medical Electronics Co, QIAGEN, PerkinElmer Inc, Meso Scale Diagnostics, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A Luminex Corporation, Bio-Rad Laboratories, Global Immunoassay Market Competitive Landscape Analysis The report has the competitive landscape analysis, which details the most significant competitors operating in a global industry. The overall comparison is done based on overall revenue generation, key investments by venture capitalists, market initiatives, company overview, production analysis, value chain optimization, R&D investment, share financials, global presence, production capacity, production sites and facilities, potential, and various other factors. Abbott Agilent Technologies BD Beckman Coulter BioCheck bioMérieux SA Bio-Rad Laboratories Bio-Techne DiaSorin S.p.A F. Hoffmann-La Roche Ltd Luminex Corporation Merck KGaA Meso Scale Diagnostics Ortho Clinical Diagnostics PerkinElmer Inc QIAGEN Quidel Corporation Randox Laboratories Ltd Shenzhen Mindray Bio-Medical Electronics Co Siemens Thermo Fisher Scientific Recent Developments In April 2022, GeneProof, a prominent molecular diagnostics firm based in Brno, Czech Republic, merged with American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company. The merger made them a global market leader in diagnostic products with extensive capabilities covering innovative immunoassay testing kits, real-time PCR testing products, and automated laboratory instrumentation systems. In April 2022, The Simple Plex HEK 293 HCP 3G assay for automated process impurity detection on the Ella immunoassay platform was launched by Bio-Techne Corporation and Cygnus Technologies, a division of Maravai LifeSciences. In Gene and Cell Therapy applications, purifying viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. Impurity clearance is performed according to regulatory criteria to guarantee HCP, and accurate quantification throughout process phases is required. In February 2022, NOVEOS Immunoassay Analyzer gained additional FDA 510(k) clearance from Hycor Biomedical Inc, a medical device firm that makes and supplies in-vitro diagnostic equipment. The NOVEOS Immunoassay Analyzer is a chemiluminescent immunoassay analyzer that can diagnose allergies. It's made to assist with analyte concentration measurements in human samples. In September 2021, The FDA granted breakthrough device Designation to Oncuria, a revolutionary non-invasive multiplex immunoassay used to predict therapeutic response in patients with bladder cancer, as a. Nonagen Bioscience Corp's gadget analyses ten protein biomarkers in a single urine sample. Using a weighted algorithm, biomarkers are then used to help predict Bacillus Calmette-Guerin (BCG) response in patients with intermediate-to-high-risk, early-stage bladder cancer. Various Products that Key Market Leaders Develop Product Function Key players ABBOTT PRISM System Automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology. Abbott Phadia 250 Immunoassay Analyzers that Provide optimal allergy and autoimmunity testing solutions. Thermo Fisher Scientific, VIDAS Automated immunoassay system based on the Enzyme-Linked Fluorescent Assay (ELFA) principles. bioMérieux Cobas e 411 The fully automated analyzer that uses ElectroChemiLuminescence (ECL) technology for immunoassay analysis. Roche Frequently Asked Question About This Report How big is the immunoassay market? The global immunoassay market size was $24.30 Bn in 2021 and is predicted to reach $45.82 Bn by 2030 with a CAGR of 7.3% during 2021-2030. What is the valuation of the immunoassay Market? The global immunoassay market analysis shows a valuation of USD 24.30 Bn in 2021. What is the immunoassay market growth? The global immunoassay market is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2021 to 2030 to reach USD 45.82 billion by 2030. What is the overall growth rate of the Immunoassay Market? The global immunoassay market forecasts a CAGR of 7.3%. What are immunoassays used for? Immunoassays are often used in drug discovery and pharmaceutical industries, including illness diagnostics, therapeutic medication monitoring, clinical pharmacokinetics and bioequivalence investigations. Which region has the maximum share in Immunoassays Market? Global Immunoassay market trends forecast North America with the largest share. Which region holds the largest growth rate in Immunoassays Market? Asia-Pacific is projected to have the fastest growth rate in the Global Immunoassays Market. Factors affecting the Immunoassay market growth rate include high incidence rate rising Population, the evolution of the immunoassay market in India and the growing ELISA market size. Who are the key players in Immunoassays Market? Key players in Immunoassays Market Include- BD, Bio-Techne, Abbott, Agilent Technologies, Beckman Coulter, BioCheck, bioMérieux SA, Merck KGaA, Ortho Clinical Diagnostics, Randox Laboratories Ltd, Siemens, Thermo Fisher Scientific, Shenzhen Mindray Bio-Medical Electronics Co, QIAGEN, PerkinElmer Inc, Meso Scale Diagnostics, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A, Luminex Corporation, Bio-Rad Laboratories. What are some allied applications of Immunoassays? Clinical diagnostics and drug monitoring applications rapidly gain market share and vaccine development, Nephelometry and Protein microarrays. What are other Immunoassays used in molecular diagnostics? Cloned enzyme donor immunoassay (CEDIA), heterogeneous immunoassays, Label-free immunoassays, Magnetic immunoassay, Memory Lymphocyte Immunostimulant Assay (MELISA), non-competitive immunoassays, Photoacoustic Immunoassay, real-time quantitative polymerase chain reaction (RT qPCR) and Surround Optical Fiber Immunoassay (SOFIA). Source: https://www.creative-diagnostics.com/Immunoassay.htm https://pubmed.ncbi.nlm.nih.gov/8100916/ https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/ https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf https://jamanetwork.com/journals/jama/fullarticle/768249 https://www.icjournal.org/DOIx.php?id=10.3947/ic.2014.46.1.1 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220162 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Immunoassay Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Immunoassay Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021-2030 (USD Million) 4.4 By Type/ Platform Business Analysis 4.4.1 market, By Type/ Platform, 2021-2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021-2030 (USD Million) 4.6 Technique Business Analysis 4.6.1 market, By Technique, 2021-2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021-2030 (USD Million) 4.8 Product Analysis 4.8.1 market, By Product, 2021-2030 (USD Million) 4.9 Specimen Type Analysis 4.9.1 market, By Specimen Type, 2021-2030 (USD Million) 4.10 Value Chain Analysis 4.11 Market Variable Analysis 4.11.1 Market Drivers Analysis 4.11.2 Market Restraints Analysis 4.12 Business Environment Analysis Tool 4.12.1 market PEST analysis 4.12.2 market Porter’s analysis 4.13 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2020) 5.11.2. Trends in End-user (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Type/ Platform 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Type/ Platform Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Radioimmunoassay (RIA) 7.3.1. Radioimmunoassay (RIA) market, 2021-2030 (USD Million) 7.4. Enzyme Immunoassays (EIA) 7.4.1. Enzyme Immunoassays (EIA) market, 2021-2030 (USD Million) 7.5. Fluoro immunoassay (FIA) 7.5.1. Fluoro immunoassay (FIA) market, 2021-2030 (USD Million) 7.6. Chemiluminescence immunoassay (CLIA) 7.6.1. Chemiluminescence immunoassay (CLIA) market, 2021-2030 (USD Million) 7.7. Electrochemiluminescence immunoassay (ECL) 7.7.1. Electrochemiluminescence immunoassay (ECL) market, 2021-2030 (USD Million) 7.8. Colloidal Gold Immunochromatographic Assay 7.8.1. Colloidal Gold Immunochromatographic Assay market, 2021-2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Infectious Diseases 8.3.1. Infectious Diseases market, 2021-2030 (USD Million) 8.4. Respiratory Disease 8.4.1. Respiratory Disease market, 2021-2030 (USD Million) 8.5. Oncology or Cancer Diagnostics 8.5.1. Oncology or Cancer Diagnostics market, 2021-2030 (USD Million) 8.6. Hematology 8.6.1. Hematology market, 2021-2030 (USD Million) 8.7. Cardiology 8.7.1. Cardiology market, 2021-2030 (USD Million) 8.8. Endocrinology 8.8.1. Endocrinology market, 2021-2030 (USD Million) 8.9. Thyroid 8.9.1. Thyroid market, 2021-2030 (USD Million) 8.10. Allergies 8.10.1. Allergies market, 2021-2030 (USD Million) 8.11. Others 8.11.1. Others market, 2021-2030 (USD Million) 9. Market: By Technique Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Western Blotting 9.3.1. Western Blotting market, 2021-2030 (USD Million) 9.4. Enzyme-Linked Immunosorbent Assays 9.4.1. Enzyme-Linked Immunosorbent Assays market, 2021-2030 (USD Million) 9.5. Immuno-PCR (I-PCR) 9.5.1. Immuno-PCR (I-PCR) market, 2021-2030 (USD Million) 9.6. Rapid Tests 9.6.1. Rapid Tests market, 2021-2030 (USD Million) 9.7. Enzyme-Linked Immunospot 9.7.1. Enzyme-Linked Immunospot market, 2021-2030 (USD Million) 9.8. CD/DVD based immunoassay 9.8.1. CD/DVD based immunoassay market, 2021-2030 (USD Million) 9.9. Other Techniques 9.9.1. Other Techniques market, 2021-2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021-2030 (USD Million) 10.4. Pharma & Biotech Companies 10.4.1. Pharma & Biotech Companies market, 2021-2030 (USD Million) 10.5. Clinical Laboratories 10.5.1. Clinical Laboratories market, 2021-2030 (USD Million) 10.6. Others 10.6.1. Others market, 2021-2030 (USD Million) 11. Market: By Product Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Reagents and Kits 11.3.1. Reagents and Kits market, 2021-2030 (USD Million) 11.4. Analyzers 11.4.1. Analyzers market, 2021-2030 (USD Million) 12. Market: By Specimen Type Segment Analysis 12.1. Introduction 12.2. Sales Volume & Revenue Analysis (2021-2030) 12.3. Blood 12.3.1. Blood market, 2021-2030 (USD Million) 12.4. Saliva 12.4.1. Saliva market, 2021-2030 (USD Million) 12.5. Urine 12.5.1. Urine market, 2021-2030 (USD Million) 12.6. Others 12.6.1. Others market, 2021-2030 (USD Million) 13. Market: Regional Outlook 13.1 North America 13.1.1. North America market, By Type/ Platform, 2021-2030 (USD Million) 13.1.2. North America market, By Application, 2021-2030 (USD Million) 13.1.3. North America market, by End-user, 2021-2030 (USD Million) 13.1.4. North America market, by Specimen Type, 2021-2030 (USD Million) 13.1.5. North America market, by Product, 2021-2030 (USD Million) 13.1.6. North America market, by Country, 2021-2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Type/ Platform, 2021-2030 (USD Million) 12.1.4.1.2. U.S. market, By Application, 2021-2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021-2030 (USD Million) 12.1.4.1.4. U.S. market, by Specimen Type, 2021-2030 (USD Million) 12.1.4.1.5. U.S. market, by Product, 2021-2030 (USD Million) 12.1.4.1.6. U.S. market, by Country, 2021-2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Type/ Platform, 2021-2030 (USD Million) 12.1.4.2.2. Canada market, By Application, 2021-2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021-2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Type/ Platform, 2021-2030 (USD Million) 12.2.2. Europe market, By Application, 2021-2030 (USD Million) 12.2.3. Europe market, by End-user, 2021-2030 (USD Million) 12.2.4. Europe market, by Specimen Type, 2021-2030 (USD Million) 12.2.5. Europe market, by Product, 2021-2030 (USD Million) 12.2.6. Europe market, by country, 2021-2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.1.2. U.K. market, By Application, 2021-2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021-2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021-2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021-2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.3.2. France market, By Application, 2021-2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021-2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Application, 2021-2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021-2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Type/ Platform, 2021-2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021-2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021-2030 (USD Million) 12.3.4. Asia Pacific market, by Specimen Type, 2021-2030 (USD Million) 12.3.5. Asia Pacific market, by Product, 2021-2030 (USD Million) 12.3.6. Asia Pacific market, by country, 2021-2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.1.2. China market, By Application, 2021-2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021-2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.2.2. India market, By Application, 2021-2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021-2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.3.2. Japan market, By Application, 2021-2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021-2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.4.2. South Korea market, By Application, 2021-2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021-2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021-2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021-2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Type/ Platform, 2021-2030 (USD Million) 12.4.2. Latin America market, By Application, 2021-2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021-2030 (USD Million) 12.4.4. Latin America market, by Specimen Type, 2021-2030 (USD Million) 12.4.5. Latin America market, by product, 2021-2030 (USD Million) 12.4.6. Latin America market, by Technique, 2021-2030 (USD Million) 12.4.7. Latin America market, by country, 2021-2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.1.2. Brazil market, By Application, 2021-2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021-2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.2.2. Mexico market, By Application, 2021-2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021-2030 (USD Million) 12.4.4.3. Rest of the Latin America 12.4.4.3.1. Rest of the Latin America market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Application, 2021-2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021-2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Type/ Platform, 2021-2030 (USD Million) 12.5.2. MEA market, By Application, 2021-2030 (USD Million) 12.5.3. MEA market, by End-user, 2021-2030 (USD Million) 12.5.4. MEA market, by Technique, 2021-2030 (USD Million) 12.5.4. MEA market, by Specimen Type, 2021-2030 (USD Million) 12.5.4. MEA market, by Region, 2021-2030 (USD Million) 13. Competitive Landscape 13.1 Abbott 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Type/ Platform Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Agilent Technologies 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Type/ Platform Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. BD 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Type/ Platform Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Beckman Coulter 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Type/ Platform Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. BioCheck 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Type/ Platform Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. bioMérieux SA 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Type/ Platform Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Bio-Rad Laboratories 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Type/ Platform Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Bio-Techne 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Type/ Platform Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. DiaSorin S.p.A 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Type/ Platform Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. F. Hoffmann-La Roche Ltd 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Type/ Platform Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. Luminex Corporation 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Type/ Platform Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Merck KGaA 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Type/ Platform Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Meso Scale Diagnostics 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Type/ Platform Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. Ortho Clinical Diagnostics 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Type/ Platform Portfolio Analysis 13.14.4. Business Strategy & Recent Development 13.15. PerkinElmer Inc 13.15.1. Company overview 13.15.2. Financial performance 13.15.3. Type/ Platform Portfolio Analysis 13.15.4. Business Strategy & Recent Development 13.16. QIAGEN 13.16.1. Company overview 13.16.2. Financial performance 13.16.3. Type/ Platform Portfolio Analysis 13.16.4. Business Strategy & Recent Development 13.17. Quidel Corporation 13.17.1. Company overview 13.17.2. Financial performance 13.17.3. Type/ Platform Portfolio Analysis 13.17.4. Business Strategy & Recent Development 13.18. Randox Laboratories Ltd 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Shenzhen Mindray Bio-Medical Electronics Co 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Siemens 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Thermo Fisher Scientific 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development List of Tables (86 Tables) TABLE 1. MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 2. MARKET FOR Radioimmunoassay (RIA), BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Enzyme Immunoassays (EIA), BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Fluoro immnoassay (FIA), BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Chemiluminescence immunoassay (CLIA), BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Electrochemiluminescence immunoassay (ECL), BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Colloidal Gold Immunochromatographic Assay, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, By Application, 2021-2030 (USD Million) TABLE 9. MARKET FOR Infectious Diseases, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Respiratory Disease, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Oncology or Cancer Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Hematology, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Cardiology, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Endocrinology, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Thyroid, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Allergies, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 19. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET FOR Pharma & Biotech Companies, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Clinical Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET, By Technique, 2021-2030 (USD Million) TABLE 24. MARKET FOR Western Blotting, BY REGION, 2021-2030 (USD Million) TABLE 25. MARKET FOR Enzyme-Linked Immunosorbent Assays, BY REGION, 2021-2030 (USD Million) TABLE 26. MARKET FOR Immuno-PCR (I-PCR), BY REGION, 2021-2030 (USD Million) TABLE 27. MARKET FOR Rapid Tests, BY REGION, 2021-2030 (USD Million) TABLE 28. MARKET FOR Enzyme-Linked Immunospot, BY REGION, 2021-2030 (USD Million) TABLE 29. MARKET FOR CD/DVD based immunoassay, BY REGION, 2021-2030 (USD Million) TABLE 30. MARKET FOR Other Techniques, BY REGION, 2021-2030 (USD Million) TABLE 31. MARKET, By Product, 2021-2030 (USD Million) TABLE 32. MARKET FOR Reagents and Kits, BY REGION, 2021-2030 (USD Million) TABLE 33. MARKET FOR Analyzers, BY REGION, 2021-2030 (USD Million) TABLE 34. MARKET, By Specimen Type, 2021-2030 (USD Million) TABLE 35. MARKET FOR Blood, BY REGION, 2021-2030 (USD Million) TABLE 36. MARKET FOR Saliva, BY REGION, 2021-2030 (USD Million) TABLE 37. MARKET FOR Urine, BY REGION, 2021-2030 (USD Million) TABLE 38. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 39. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 40. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 41. NORTH AMERICA MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 42. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 43. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 44. NORTH AMERICA MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 45. NORTH AMERICA MARKET, BY Product, 2021-2030 (USD Million) TABLE 46. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 47. EUROPE MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 48. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 49. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 50. EUROPE MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 51. EUROPE MARKET, BY Product, 2021-2030 (USD Million) TABLE 52. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 53. ASIA-PACIFIC MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 54. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 55. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 56. ASIA-PACIFIC MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 57. ASIA-PACIFIC MARKET, BY Product, 2021-2030 (USD Million) TABLE 58. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 59. LAMEA MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 60. LAMEA MARKET, By Technique, 2021-2030 (USD Million) TABLE 61. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 62. LAMEA MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 63. LAMEA MARKET, BY Product, 2021-2030 (USD Million) TABLE 64. Abbott: COMPANY SNAPSHOT TABLE 65. Abbott: OPERATING SEGMENTS TABLE 66. Agilent Technologies: COMPANY SNAPSHOT TABLE 67. Agilent Technologies: OPERATING SEGMENTS TABLE 68. BD: COMPANY SNAPSHOT TABLE 69. BD: OPERATING SEGMENTS TABLE 70. Beckman Coulter: COMPANY SNAPSHOT TABLE 71. Beckman Coulter: OPERATING SEGMENTS TABLE 72. BioCheck: COMPANY SNAPSHOT TABLE 73. BioCheck: OPERATING SEGMENTS TABLE 74. bioMérieux SA: COMPANY SNAPSHOT TABLE 75. bioMérieux SA: OPERATING SEGMENTS TABLE 76. Bio-Rad Laboratories: COMPANY SNAPSHOT TABLE 77. Bio-Rad Laboratories: OPERATING SEGMENTS TABLE 78. Bio-Techne: COMPANY SNAPSHOT TABLE 79. Bio-Techne: OPERATING SEGMENTS TABLE 80. DiaSorin S.p.A: COMPANY SNAPSHOT TABLE 81. DiaSorin S.p.A: OPERATING SEGMENTS TABLE 82. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT TABLE 83. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS TABLE 84. Luminex Corporation: COMPANY SNAPSHOT TABLE 85. Luminex Corporation: OPERATING SEGMENTS TABLE 86. Merck KGaA: COMPANY SNAPSHOT TABLE 87. Merck KGaA: OPERATING SEGMENTS TABLE 88. Meso Scale Diagnostics: COMPANY SNAPSHOT TABLE 89. Meso Scale Diagnostics: OPERATING SEGMENTS TABLE 90. Ortho Clinical Diagnostics: COMPANY SNAPSHOT TABLE 91. Ortho Clinical Diagnostics: OPERATING SEGMENTS TABLE 92. PerkinElmer Inc: COMPANY SNAPSHOT TABLE 93. PerkinElmer Inc: OPERATING SEGMENTS TABLE 94. QIAGEN: COMPANY SNAPSHOT TABLE 95. QIAGEN: OPERATING SEGMENTS TABLE 96. Quidel Corporation: COMPANY SNAPSHOT TABLE 97. Quidel Corporation: OPERATING SEGMENTS TABLE 98. Randox Laboratories Ltd: COMPANY SNAPSHOT TABLE 99. Randox Laboratories Ltd: OPERATING SEGMENTS TABLE 100. Shenzhen Mindray Bio-Medical Electronics Co: COMPANY SNAPSHOT TABLE 101. Shenzhen Mindray Bio-Medical Electronics Co: OPERATING SEGMENTS TABLE 102. Siemens: COMPANY SNAPSHOT TABLE 103. Siemens: OPERATING SEGMENTS TABLE 104. Thermo Fisher Scientific: COMPANY SNAPSHOT TABLE 105. Thermo Fisher Scientific: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Type/ Platform-Based Estimation Figure 6 Top 21 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Type/ Platform, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Technique, 2019 vs. 2025 (USD Million) Figure 16 Market Share, By Specimen Type, 2019 vs. 2025 (USD Million) Figure 17 Geographical Snapshot of the Market Figure 18 Enzyme Immunoassays (EIA) to Witness Higher CAGR in Market for Type/ Platform Segment during Forecast Period. Figure 19 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 20 Enzyme-Linked Immunosorbent Assays to Witness Higher CAGR in Market for Technique Segment during Forecast Period. Figure 21 Reagents and Kits to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 22 Blood to Witness Higher CAGR in Market for Specimen Type Segment during Forecast Period. Figure 23 Infectious Diseases to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 24 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 25 Market: Drivers, Restraints, Opportunities, and Challenges Figure 26 North America: Market Snapshot Figure 27 Asia Pacific: Market Snapshot Figure 28 Vendor Dive: Evaluation Overview